Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Survey FL8 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for mature B‑cell leukemia/lymphoma.
- Two 1.1‑mL specimens containing a cell line/whole blood mixture simulating mature B‑cell leukemia/lymphoma minimal residual disease with clinical history
- One case with clinical history and gated dot plots
- Shipment A: February 9
- Shipment B: August 3